> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Dyax’s Takhzyro
- URL: https://www.fdaweb.com/regulatory-review-period-for-dyaxs-takhzyro/
- Published: 2020-09-11T12:00:00.000Z
- Updated: 2026-09-14T16:28:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147633

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Dyax Corp.’s Takhzyro (lanadelumab-flyo), indicated for prophylaxis to prevent hereditary angioedema in patients 12 years and older. The regulatory review period was determined to be 1,857 days, which includes 1,616 days that occurred during the testing phase and 241 days during the approval phase. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-20104.pdf?ref=fdaweb.com).